Determination of 5-fluorouracil and dihydrofluorouracil levels by using a liquid chromatography-tandem mass spectrometry method for evaluation of dihydropyrimidine dehydrogenase enzyme activity

Serdar M. A., Sertoglu E., Uyanik M., Tapan S., Akin O., Cihan M.

CANCER CHEMOTHERAPY AND PHARMACOLOGY, cilt.68, sa.2, ss.525-529, 2011 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 68 Sayı: 2
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1007/s00280-010-1528-1
  • Dergi Adı: CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.525-529
  • Anahtar Kelimeler: Dihydropyrimidine dehydrogenase, 5-Fluorouracil, Dihydrofluorouracil, LC-MS/MS, BLOOD MONONUCLEAR-CELLS, CANCER-PATIENTS, DPD DEFICIENCY, TOXICITY, IDENTIFICATION, MUTATIONS, INFUSION, PATIENT, LIVER, COLON
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Purpose 5-Fluorouracil (5-FU), acting as a pyrimidine antagonist, is a major chemotherapy drug used for the treatment of tumors such as gastrointestinal, breast, ovary, and head and neck cancers. The key and rate-limiting enzyme in 5-FU catabolism is dihydropyrimidine dehydrogenase (DHPDH), whose partial or complete deficiency exposes to a severe 5-FU toxicity in patients. The determination of DHPDH activity in patients before the treatment and setting up a personalized therapy for each patient receiving the drug can help us to prevent the possible risk of toxicity.